Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats by Albarellos, Gabriela A. et al.
Original Research
doi:10.4102/jsava.v84i1.968http://www.jsava.co.za
Pharmacokinetics and skin concentrations of lincomycin 
after intravenous and oral administration to cats 
Authors:
Gabriela A. Albarellos1
Laura Montoya1
Graciela A.A. Denamiel1
Sabrina M. Passini1
María F. Landoni2
Affiliations:
1Cátedra de Farmacología, 
Universidad de Buenos Aires, 
Argentina
2Cátedra de Farmacología, 
Universidad Nacional de La 
Plata, Argentina
Correspondence to: 
Gabriela Albarellos
Email: 
albarell@fvet.uba.ar 
Postal address: 
Chorroarín 280, Buenos Aires 
1427, Argentina
Dates:
Received: 11 Dec. 2012
Accepted: 02 July 2013
Published: 31 Oct. 2013
How to cite this article: 
Albarellos, G.A., Montoya, 
L., Denamiel, G.A.A., Passini, 
S.M. & Landoni, M.F., 2013, 
‘Pharmacokinetics and skin 
concentrations of lincomycin 
after intravenous and oral 
administration to cats’, 
Journal of the South African 
Veterinary Association 84(1), 
Art. #968, 5 pages. http://
dx.doi.org/10.4102/jsava.
v84i1.968 
Copyright:
© 2013. The Authors.
Licensee: AOSIS 
OpenJournals. This work
is licensed under the
Creative Commons
Attribution License.
The aim of the present study was to describe the plasma pharmacokinetic profile and skin 
concentrations of lincomycin after intravenous administration of a 15% solution and oral 
administration of 300 mg tablets at a dosing rate of 15 mg/kg to cats. Susceptibility of 
staphylococci (n = 31) and streptococci (n = 23) strains isolated from clinical cases was also 
determined. Lincomycin plasma and skin concentrations were determined by microbiological 
assay using Kocuria rhizophila ATCC 9341 as test microorganism. Susceptibility was established 
by the antimicrobial disc diffusion test. Individual lincomycin plasma concentration–time 
curves were analysed by a non-compartmental approach. After intravenous administration, 
volume of distribution, body clearance and elimination half-life were 0.97 L/kg ± 0.15 L/kg, 
0.17 L/kg ± 0.06 L/h.kg and 4.20 h ± 1.12 h, respectively. After oral administration, peak plasma 
concentration, time of maximum plasma concentration and bioavailability were 22.52 µg/mL 
± 10.97 µg/mL, 0.80 h ± 0.11 h and 81.78% ± 24.05%, respectively. Two hours after lincomycin 
administration, skin concentrations were 17.26 µg/mL ± 1.32 µg/mL (intravenous) and 
16.58 µg/mL ± 0.90 µg/mL (oral). The corresponding skin: plasma ratios were 2.08 ± 0.47 
(intravenous) and 1.84 ± 0.97 (oral). The majority of staphylococci and streptococci tested in 
this study were susceptible to lincosamides (87.09% and 69.56%, respectively). In conclusion, 
lincomycin administered orally at the assayed dose showed a good pharmacokinetic profile, 
with a long elimination half-life and effective skin concentration. Therefore, it could be a good 
first option for treating skin infections in cats.
Introduction 
Lincomycin is, as clindamycin, a lincosamide antibiotic mainly active against staphylococci, 
streptococci and anaerobic bacteria (Giguère 2006). It is recommended for treating skin and other 
soft tissue infections produced by susceptible bacteria in dogs and cats (Papich & Riviere 2009). 
Lincosamides are antibiotics classified as ‘important’ (instead of ‘critically important’ or ‘highly 
important’) based on their importance in human medicine (WHO 2005, cited by Collignon, 
Courvalin & Aidara-Kane 2008) and would therefore be a better alternative to other antibiotics 
for the treatment of bacterial infections in animals (Collignon et al. 2008).
Lincomycin achieves therapeutic concentrations in most body tissues (Giguère 2006) and is 
widely metabolised in the liver to inactive metabolites that are eliminated through bile and urine 
(Brown et al. 1975; Hornish, Gosline & Nappier 1987).
Lincomycin pharmacokinetics have been studied in calves (Burrows, Barto & Weeks 1986), pigs 
(Kuroha, Son & Shimoda 2001; Nielsen & Gyrd-Hansen 1998), sheep (Ziv & Sulman 1973), goats 
(Abo El-Sooud, Goudah & Abd El-Aty 2004), chickens (Soback et al. 1987) and cats (Albarellos 
et al. 2012). However, to the authors’ knowledge there is no published information on lincomycin 
pharmacokinetic behaviour after oral administration in cats.
The aim of this study was to characterise the plasma pharmacokinetic profile and skin 
concentrations of lincomycin after intravenous and oral administration in domestic cats.
Materials and methods
Experiment animals
Experimental animals were five adult (5-year-olds) mixed-breed cats, with an average weight 
of 4.95 kg ± 0.55 kg. All cats were healthy, as determined by clinical examination, complete blood 
and plasma biochemical analysis and urinalysis. Animals were housed in facilities at the Faculty 
of Veterinary Medicine, University of Buenos Aires and allowed to acclimatise for two months 
before the experiment. Access to a high-quality commercial dry food (Royal Canin®, Argentina) 
and water was available ad libitum before the study. All animal procedures were approved by 
the Institutional Animal Care and Use Committee, School of Veterinary Science, University of 
Buenos Aires, Argentina. 
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Dosage form
A 15% lincomycin aqueous solution (Tritonyl inyectable®, 
Triton Vet S.R.L., Argentina) was used for intravenous 
administration. The dose (15 mg/kg) was half diluted 
with saline (NaCl 0.9%) before administration and infused 
over a 3 min period. For the oral administration, marked 
300 mg lincomycin tablets (Tritonyl 300®, Triton Vet S.R.L, 
Argentina) were used. Each animal received 75 mg (each 
tablet was divided into quarters).
Experiment design
The study was carried out in a randomised cross-over design 
with a two week washout period. 
Lincomycin was administered intravenously (15 mg/kg) 
through a 24G catheter (Abbocath-T, Venisystems, 
Abbott, Ireland) placed into the cephalic vein. For oral 
administration, a quarter tablet was administered per 
cat (actual dose of 15.19 mg/kg ± 1.65 mg/kg). Cats were 
deprived of access to food for 12 h prior to the study and up 
to 6 h post administration.
Blood sampling
For blood collection, a jugular vein was catheterised 24 h 
before each study according to a technique described 
previously (Albarellos et al. 2003). 
The same blood sampling schedule was used for both phases 
of the study. Blood samples (0.7 mL) were collected through 
the jugular catheter prior to antibiotic administration and 
at the following post-administration times: 5 min, 10 min, 
20 min, 30 min, 45 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 
10 h and 12 h.
  
Samples were collected into heparinised tubes, mixed and 
placed on ice until plasma separation 30 min later. Plasma 
was separated after centrifugation (1500 g, 15 min) and 
stored at –20 °C until analysis. All samples were assayed in 
the week after collection. 
Skin sampling
Skin samples (1 cm2) were collected under general 
anaesthesia (tiletamine/zolazepam 10 mg/kg, Zelazol, Fort 
Dodge, Pfizer S.R.L., Argentina) from the loose skin over 
the shoulders two hours after lincomycin was administered 
(either intravenously or orally). Samples were rinsed briefly 
with saline solution, dried with sterile gauze, weighed and 
stored at –20 °C.
To avoid heat inactivation of the antibiotic, skin samples 
were carefully and slowly cut to small pieces (≈1 mm3). 
Lincomycin was eluted using the technique described by 
Bamberger et al. (2005). Briefly, samples were incubated in 
0.1 m phosphate buffer pH 7.8 (in a ratio 1:2 w/v) for 24 h at 
4 °C, applying agitation during the first 40 min of incubation. 
Samples were subsequently centrifuged (1500 g, 15 min) and 
the supernatant fluid was collected.  
Lincomycin determination
Lincomycin plasma and skin concentrations were determined 
by microbiological assay (Bennet et al. 1966) using Kocuria 
rhizophila (formerly Micrococcus luteus) ATCC 9341 as test 
microorganism. This method was selected because of its 
sensitivity, simplicity and good correlation with high-
performance liquid chromatography (HPLC) determination 
(Strachunskii et al. 1993). Standard curves were prepared, 
depending on the sample matrix to be quantified, on 
normal cat plasma or phosphate buffer pH 7.8. Each sample 
was seeded in triplicate and each standard dilution in 
quintuplicate. The limits of detection and quantification 
of the method for plasma and phosphate buffer were 
0.78 µg/mL and 1.56 µg/mL, respectively. The method was 
linear between 0.78 µg/mL and 50 µg/mL (r = 0.9965). Inter- 
and intra-assay coefficients of variation were less than 10%. 
Pharmacokinetic analysis
Individual lincomycin plasma concentration–time curves 
were analysed by a non-compartmental approach with 
a software programme (PCNONLIN 4.0, SCI Software, 
Lexington, KY, USA). Major pharmacokinetic parameters 
were calculated according to classical equations (Gibaldi & 
Perrier 1982). The observed maximum plasma concentration 
(Cmax) and time of maximum plasma concentration (Tmax) 
were recorded directly from the data. The apparent terminal 
rate constant, kz, was determined by linear regression of the 
last five or six points on the terminal phase of the logarithmic 
plasma concentration–time curves. 
Statistical analysis
The means and standard deviations of pharmacokinetic 
parameters are expressed. Main pharmacokinetic parameters 
(area under the curve [AUC(0-∞)], elimination half-life [T½] and 
mean residence time [MRT]), skin concentrations and skin: 
plasma concentration ratios were compared statistically for 
the two administration routes, applying a nonparametric 
paired test (Wilcoxon test). Differences were considered 
statistically significant at p ≤ 0.05.
Susceptibility test on Staphylococcus spp. and 
Streptococcus spp.
A total of 31 Staphylococcus strains and 23 Streptococcus 
strains were isolated from skin and mucosal infections from 
clinical cases attending the Small Animals Hospital, Faculty 
of Veterinary Science, University of Buenos Aires.
Bacterial susceptibility to lincomycin was established by an 
antimicrobial disc diffusion test, using 2 µg clindamycin 
discs in accordance with CLSI (2008) recommendations. 
Staphylococcus aureus ATCC 25923 and Streptococcus 
pneumoniae ATCC 49619 were used as quality controls. 
Results
No adverse effects were observed during or following 
administration (either route) of lincomycin in any of the cats.
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The mean plasma concentration–time curves for the two 
administration methods of the antibiotic are shown in 
Figure 1. Estimated pharmacokinetic parameters for both 
administration routes are summarised in Table 1. 
Oral absorption was rapid (Tmax = 0.80 h ± 0.11 h) although 
quite variable between animals (Cmax = 22.52 µg/mL ± 
10.97 µg/mL). Lincomycin oral bioavailability (F) was almost 
complete (F = 81.78% ± 24.05%). No statistically significant 
differences were observed between pharmacokinetic 
parameters after intravenous or oral administration. 
Lincomycin skin concentrations are shown in Table 2. For 
both administration routes, the lincomycin concentrations 
were higher than the corresponding plasma concentration; 
skin: plasma ratio for intravenous and oral administration 
was 2.08 ± 0.47 and 1.84 ± 0.97, respectively. No statistically 
significant differences were observed in skin concentrations 
or skin: plasma ratios between administration routes.  
Of the tested staphylococci samples, 87.09% (27/31) were 
susceptible to lincomycin, whilst 69.56% (16/23) of the tested 
streptococci samples were susceptible to the antibiotic.
Discussion
Lincomycin is an antibiotic with long duration in the body 
owing to its lipid solubility and wide tissue distribution. It 
has good activity against Gram-positive cocci and anaerobes. 
Because of these features, lincomycin is recommended for the 
treatment of a variety of skin, respiratory, gastrointestinal, 
soft-tissue and bone infections (Greene & Boothe 2012; 
Patel 2006).
The microbiological assay for measuring lincomycin 
concentrations in plasma and other biological matrices 
has been used in many studies (Abo El-Sooud et al. 2004; 
Albarellos et al. 2011; Brown et al. 1975; Burrows et al. 1986; 
Marcus, Ziv & Glickman 1995; Nielsen & Gyrd-Hansen 
1998; Soback et al. 1987; Ziv & Sulman 1973). This analytical 
method is appropriate and accurate as lincomycin has 
no active metabolites (Brown et al. 1975; Brush et al. 1976; 
Hornish et al. 1987).
It is important to emphasise that animals were 
anaesthetised for skin sampling for approximately 
30 min. Clinical parameters were carefully monitored 
throughout the procedures and all the cats remained 
stable, but haemodynamic modifications influencing the 
pharmacokinetic behaviour of lincomycin cannot be ruled 
out. However, previous antimicrobial pharmacokinetic 
studies performed in anaesthetised dogs, although with 
a different antibiotic, showed no significant changes in 
pharmacokinetic parameters (Duval & Budsberg 1995). 
Lincomycin pharmacokinetic parameters after intravenous 
administration were similar to those reported in a previous 
study (Albarellos et al. 2012). However, the dose used in the 
present study was higher than the one used in the earlier 
study by Albarellos et al. (2012). This difference is clearly 
observed in the dose-dependent parameters that varied 
accordingly. 
Lincomycin oral absorption was rapid and almost complete 
(Tmax = 0.80 h and F = 81.78%). Similar high oral bioavailability 
was reported by Nielsen and Gyrd-Hansen (1998) after 
lincomycin administration to fasted pigs. 
No statistically significant differences were observed 
for elimination-related parameters (T½ and MRT) when 
comparing the two administration routes. 
Lincosamides are lipophilic antibiotics and are therefore 
expected to achieve higher concentrations in most tissues than 
in plasma (Giguère 2006). In a study analysing clindamycin 
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FIGURE 1: Mean (± SEM) lincomycin plasma concentration–time profile after 
intravenous and oral administration to cats at a dosing rate of 15 mg/kg (n = 5).
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TABLE 1: Pharmacokinetic parameters (mean ± s.d.) of lincomycin after 
intravenous and oral administration to cats at a dosing rate of 15 mg/kg (n = 5).
Pharmacokinetic parameter Intravenous administration Oral administration
C
p(0)
 (µg/mL) 38.84 ± 6.25 –
AUC
(0-∞)
 (µg.h/mL) 98.47 ± 40.83 97.92 ± 52.37
V
D(area) 
(L/kg) 0.97 ± 0.15 –
T
max
 (h) – 0.80 ± 0.11
C
max
 (µg/mL) – 22.52 ± 10.97
Cl
B
 (L/h.kg) 0.17 ± 0.06 –
T
½
 (h) 4.20 ± 1.12 4.12 ± 1.44
MRT (h) 5.50 ± 1.64 6.38 ± 2.22
F (%) – 81.78 ± 24.05
Note: No statistically significant differences were observed between the two routes of 
administration.
AUC
(0-∞)
, area under the plasma concentration–time curve from 0 to infinity; C
max
, maximum 
concentration; C
p(0)
, plasma concentration at 0 time; Cl
B
, body clearance; F, bioavailability; 
MRT, mean residence time; T
max
, time of maximum concentration; T
½
, elimination half-life; 
V
D(area),
 volume of distribution
TABLE 2: Lincomycin plasma and skin concentrations (mean ± s.d.) taken two 
hours after lincomycin administration and skin: plasma concentration ratio after 
intravenous and oral administration (15 mg/kg) to cats (n = 5).
Tissue concentration Intravenous administration Oral administration
Plasma (µg/mL) 8.60 ± 1.73 11.70 ± 7.18
Skin (µg/g) 17.26 ± 1.32 16.58 ± 0.90
Skin: plasma ratio 2.08 ± 0.47 1.84 ± 0.97
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tissue concentrations in cats, Brown et al. (1990) found tissue: 
plasma ratios > 1. In the present study we found similar 
results. Lincomycin skin concentrations were higher than 
the corresponding plasma concentrations and skin: plasma 
ratios were also > 1,  reflecting lincomycin accumulation in this 
tissue. However, it was noted that whole tissue concentrations 
are difficult to interpret because they represent the sum of 
all concentrations (intracellular, extracellular fluid and also 
any remaining blood contamination). It is also important to 
note that in the present study skin samples were taken at a 
single time point (2 h after antibiotic administration) and a 
single dose was administered. Therefore, the expected tissue 
accumulation in an ordinary therapeutic treatment could not 
be analysed. 
Lincomycin skin concentrations and skin: plasma ratios 
were equivalent for both administration routes assayed. This 
finding is in accordance with the similar plasma concentration 
profile of the drug for the two administration routes and its 
high oral bioavailability.
Plasma lincomycin concentrations after intravenous or oral 
administration were well above MIC50 values recorded in 
literature (Albarellos et al. 2012; Giguère 2006) for the entire 
proposed dosing interval for this antibiotic (8 h – 12 h) (Plumb 
2011). According to results of this study, a 15 mg/kg oral 
dose of lincomycin could allow a 12 h dosing interval in cats.
Similarly, lincomicyn skin concentrations were above an MIC50 
of 1 µg/mL, but this refers to a single time point. However, it 
is possible to assume that lincomycin accumulates in tissues 
(because of its chemical characteristics) and therefore tissue 
concentrations will remain above plasma concentrations 
throughout the dosing interval.
Most of the staphylococci and streptococci samples tested 
in this study were susceptible to lincosamides (87.09% and 
69.56%, respectively); however, it is important to consider 
that lincomycin antibacterial activity could be overestimated 
because antimicrobial susceptibility was evaluated with 
clindamycin discs (a more potent lincosamide) (CLSI 2008). 
Nevertheless, bacterial susceptibility rates for lincomycin 
found in this study suggest that lincomycin could be a good 
first option for treating the majority of skin infections 
in cats. 
Conclusion
According to the data obtained in this study, lincomycin 
would be a useful alternative for the treatment of 
uncomplicated skin infections in cats.
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